{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:02:34Z","timestamp":1787806954078,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.resinv.2024.08.011","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T06:24:42Z","timestamp":1725863082000},"page":"1037-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged \u226560 years: A phase 1, randomized, observer-blind, placebo-controlled trial"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3007-6818","authenticated-orcid":false,"given":"David","family":"Fitz-Patrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6228-0018","authenticated-orcid":false,"given":"Hanako","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runa","family":"Mithani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0692-4201","authenticated-orcid":false,"given":"Lauren","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana K.","family":"Simorellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4957-8204","authenticated-orcid":false,"given":"Catherine A.","family":"Panozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4855-514X","authenticated-orcid":false,"given":"Eleanor","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia K.","family":"Stoszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0471-206X","authenticated-orcid":false,"given":"Christine A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.08.011_bib1","article-title":"Respiratory syncytial virus infection in adults","volume":"366","author":"Nam","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.resinv.2024.08.011_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.13.1.1","article-title":"Respiratory syncytial virus genetic and antigenic diversity","volume":"13","author":"Sullender","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.resinv.2024.08.011_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.08.011_bib4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/irv.13043","article-title":"Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults","volume":"16","author":"Branche","year":"2022","journal-title":"Influenza and Other Respiratory Viruses"},{"key":"10.1016\/j.resinv.2024.08.011_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.resinv.2024.08.011_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices \u2014 United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.resinv.2024.08.011_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/irv.12928","article-title":"Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged \u226565 years in community: a prospective cohort study in Japan","volume":"16","author":"Kurai","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"4","key":"10.1016\/j.resinv.2024.08.011_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02688-2020","article-title":"Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study","volume":"57","author":"Korsten","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.08.011_bib9","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.08.011_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2217\/fvl-2023-0069","article-title":"Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults","volume":"18","author":"Igarashi","year":"2023","journal-title":"Future Virol"},{"key":"10.1016\/j.resinv.2024.08.011_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40121-023-00777-2","article-title":"Targeted literature review of the burden of respiratory syncytial infection among high-risk and elderly patients in Asia pacific region","volume":"12","author":"Kurai","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"5","key":"10.1016\/j.resinv.2024.08.011_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.11150\/kansenshogakuzasshi.90.645","article-title":"Clinical characteristics of adult onset RSV infection during two consecutive winter seasons [in Japanese]","volume":"90","author":"Takahashi","year":"2016","journal-title":"Kansenshogaku Zasshi"},{"issue":"2","key":"10.1016\/j.resinv.2024.08.011_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.resinv.2024.08.011_bib14","unstructured":"ABRYSVO[https:\/\/www.fda.gov\/vaccines-blood-biologics\/abrysvo]."},{"key":"10.1016\/j.resinv.2024.08.011_bib15","unstructured":"First RSV vaccine to protect infants up to 6 months of age and older adults [https:\/\/www.ema.europa.eu\/en\/news\/first-rsv-vaccine-protect-infants-6-months-age-older-adults]."},{"key":"10.1016\/j.resinv.2024.08.011_bib16","unstructured":"First vaccine to protect older adults from respiratory syncytial virus (RSV) infection[https:\/\/www.ema.europa.eu\/en\/news\/first-vaccine-protect-older-adults-respiratory-syncytial-virus-rsv-infection]."},{"key":"10.1016\/j.resinv.2024.08.011_bib17","unstructured":"FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine [https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine]."},{"key":"10.1016\/j.resinv.2024.08.011_bib18","unstructured":"Japan\u2019s Ministry of Health, Labour and Welfare approves GSK's Arexvy, the country's first respiratory syncytial virus (RSV) vaccine for older adults[https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/japan-s-ministry-of-health-labour-and-welfare-approves-gsk-s-arexvy\/]."},{"key":"10.1016\/j.resinv.2024.08.011_bib19","unstructured":"Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO\u2122 for RSV [https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-broadens-portfolio-respiratory-vaccines-recommended]."},{"key":"10.1016\/j.resinv.2024.08.011_bib20","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.08.011_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"issue":"suppl 2","key":"10.1016\/j.resinv.2024.08.011_bib22","article-title":"234. Safety and immunogenicity of mRNA-1345, an mRNA-based RSV vaccine in younger and older adult cohorts: results from a phase 1, randomized clinical trial","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.resinv.2024.08.011_bib23","unstructured":"Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, has met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults[https:\/\/investors.modernatx.com\/news\/news-details\/2023\/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults\/default.aspx]."},{"key":"10.1016\/j.resinv.2024.08.011_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.resinv.2024.08.011_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100746","article-title":"mRNA vaccines: a matter of delivery","volume":"32","author":"Cao","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.resinv.2024.08.011_bib26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.resinv.2022.11.003","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: a phase I, randomized, observer-blind clinical trial","volume":"61","author":"Kotb","year":"2023","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2024.08.011_bib27","unstructured":"Guidelines on the quality, safety and efficacy of respiratory syncytial virus vaccines[www.who.int\/docs\/default-source\/biologicals\/ecbs\/rsv-guidelines-post-ecbs.pdf?sfvrsn=e9176411_2]."},{"key":"10.1016\/j.resinv.2024.08.011_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clin Microbiol Rev"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:50:53Z","timestamp":1732092653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524001321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2212534524001321"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.08.011","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged \u226560 years: A phase 1, randomized, observer-blind, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}